Clinical Trial Evidence for Treatment of Depression in Heart Failure

被引：10

作者：

Echols, Melvin R. ^{[1
]}

Jiang, Wei ^{[2
,3
]}

机构：

[1] Duke Univ, Med Ctr, Duke Clin Res Inst, Dept Internal Med, Durham, NC 27710 USA

[2] Duke Univ, Med Ctr, Dept Psychiat & Behav Sci, Durham, NC 27710 USA

[3] Duke Univ, Med Ctr, Dept Internal Med, Durham, NC 27710 USA

来源：

HEART FAILURE CLINICS | 2011年 / 7卷 / 01期

关键词：

Depression; Heart failure; Depression treatment; MAJOR DEPRESSION; DOUBLE-BLIND; MORTALITY; PLACEBO; DISEASE; IMIPRAMINE; MORBIDITY; BUPROPION; SAFETY; RISK;

D O I：

10.1016/j.hfc.2010.08.004

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Depression is an important disease state that requires a significant amount of time and resources for proper management. The presence of depression in patients with cardiovascular disease has been strongly associated with detrimental effects in terms of morbidity and mortality. Little is known about the management of depression in heart failure patients, although several investigators continue to pursue optimal treatment strategies for depression in this population. While limited, the prospective clinical trial data evaluating interventions for depression management in patients with heart failure continue to produce promising findings for progressive and improved management of both depression and heart failure.

引用

页码：81 / +

页数：9

共 30 条

[1] Effects of antidepressant treatment on cognitive performance in elderly subjects with heart failure and comorbid major depression: An exploratory study
Alves, Tania C. T. F.
Rays, Jairo
Telles, Renata M. S.
Junior, Renerio Fraguas
Wajngarten, Mauricio
Romano, Belkiss W.
Watanabe, Cintia
Busatto, Geraldo F.
[J]. PSYCHOSOMATICS, 2007, 48 (01) : 22 - 30
[2] Rationale and design of a randomised, controlled, multicenter trial investigating the effects of selective serotonin re-uptake inhibition on morbidity, mortality and mood in depressed heart failure patients (MOOD-HF)
Angermann, Christiane E.
Gelbrich, Goetz
Stoerk, Stefan
Fallgatter, Andreas
Deckert, Juergen
Faller, Hermann
Ertl, Georg
[J]. EUROPEAN JOURNAL OF HEART FAILURE, 2007, 9 (12) : 1212 - 1222
[3] Berkman LF, 2003, JAMA-J AM MED ASSOC, V289, P3106
[4] MORTALITY AND MORBIDITY IN PATIENTS RECEIVING ENCAINIDE, FLECAINIDE, OR PLACEBO - THE CARDIAC-ARRHYTHMIA SUPPRESSION TRIAL
ECHT, DS
LIEBSON, PR
MITCHELL, LB
PETERS, RW
OBIASMANNO, D
BARKER, AH
ARENSBERG, D
BAKER, A
FRIEDMAN, L
GREENE, HL
HUTHER, ML
RICHARDSON, DW
[J]. NEW ENGLAND JOURNAL OF MEDICINE, 1991, 324 (12) : 781 - 788
[5] THE SAFETY OF TRICYCLIC ANTIDEPRESSANTS IN CARDIAC PATIENTS - RISK-BENEFIT RECONSIDERED
GLASSMAN, AH
ROOSE, SP
BIGGER, JT
[J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1993, 269 (20): : 2673 - 2675
[6] THE USE OF IMIPRAMINE IN DEPRESSED-PATIENTS WITH CONGESTIVE HEART-FAILURE
GLASSMAN, AH
JOHNSON, LL
GIARDINA, EGV
WALSH, BT
ROOSE, SP
COOPER, TB
BIGGER, JT
[J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1983, 250 (15): : 1997 - 2001
[7] A double-blind placebo-controlled pilot study of controlled-release paroxetine on depression and quality of life in chronic heart failure
Gottlieb, Stephen S.
Kop, Willem J.
Thomas, Sue A.
Katzen, Scott
Vesely, Mark R.
Greenberg, Nancy
Marshall, Joanne
Cines, Michelle
Minshall, Stacey
[J]. AMERICAN HEART JOURNAL, 2007, 153 (05) : 868 - 873
[8] GREENBERG HM, 1995, BRIT HEART J, V74, P631
[9] Patients with CHF and depression have greater risk of mortality and morbidity than patients without depression
Jiang, N
Hasselblad, V
Krishnan, RR
O'Connor, CM
[J]. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2002, 39 (05) : 919 - 920
[10] Depression and heart disease - Evidence of a link, and its therapeutic implications
Jiang, W
Krishnan, RRK
O'Connor, CM
[J]. CNS DRUGS, 2002, 16 (02) : 111 - 127

← 1 2 3 →